Reshma Shinde
Featured in: 
jamanetwork.com
Articles
-
Jul 25, 2024 |
jamanetwork.com | Neil Shah |New jersey |Kristin Moore |Reshma Shinde
Key PointsQuestion What are the health care resource use, associated costs, and clinical outcomes for patients with metastatic renal cell carcinoma (mRCC) receiving first-line ipilimumab plus nivolumab (I+N) or pembrolizumab plus axitinib (P+A)?
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →